COMPANY
Clinical Phase 2
Location: Cambridge, MA · source · Oct 5, 2026
Profile checked Oct 10, 2026
Keywords: Inborn Urea Cycle Disorders Urea Cycle Disorders Ornithine Transcarbamylase (OTC) Deficiency Arginase 1 Deficiency NAGS Deficiency Carbamylphosphate Synthetase I Ornithine Transporter Mitochondrial 1 Argininosuccinate Synthase Argininosuccinate Lyase Deficiency N-acetyl Glutamate - Synthetase Citrin Deficiency Alpha-1 Anti-trypsin Deficiency AATD KRRO-121 KRRO-110
Timeline
- Trial start 1: Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD source ↗
- Raise Private placement: $85M (total, as published), announced Mar 9, 2026. Source: SEC filing. source ↗
- Trial start 1: A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 source ↗
Upcoming milestones
- 2027-08 (ESTIMATED) · 1 · Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD · NCT07773246
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $85.0M. Last 2 years.
- Private placement: $85M (total, as published), announced Mar 9, 2026. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT07773246 | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD | 1 | Recruiting | Sep 28, 2026 | 2027-08 (estimated) |
| NCT06677307 | A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | 1 | Terminated | Jan 13, 2025 | Oct 31, 2025 (actual) |
Raises and investors new
Form D raises come from the company’s own SEC filing (last 2 years).
- InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗
